BioMedNewsBreaks — Adageis CEO Discusses AI-Driven Solutions for Value-Based Care in Latest Bell2Bell Podcast 

Adageis, a healthcare technology company revolutionizing patient care through innovative digital solutions, is featured in the latest episode of The Bell2Bell Podcast, produced by IBN, a multifaceted communications organization connecting public companies with the investment community. In the interview, Adageis CEO Shane Speirs explains how the company’s AI-powered platform simplifies the administrative challenges of delivering value-based care by digitizing complex insurance and compliance processes. “We make it easy to see what measures practices need to hit and how to hit them for each individual patient,” Speirs said, noting that Adageis currently supports more than 580,000 patient lives. The conversation explores Adageis’ scalable per-provider model, rapid growth, and mission to make value-based care accessible to all providers.

To hear the full podcast, visit https://ibn.fm/a302u

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector.

For more information, visit the company’s website at www.Adageis.com

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN